This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MDVN (MDVN) (MDVN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About (MDVN) Stock (NASDAQ:MDVN) 30 days 90 days 365 days Advanced Chart Get (MDVN) alerts:Sign Up Key Stats Today's Range$81.44▼$81.4450-Day Range N/A52-Week Range$26.41▼$81.48VolumeN/AAverage Volume3.55 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc. (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe and other countries across the world for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company, in collaboration with Astellas, is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. It has developed a small molecule inhibitor of the sterol regulatory element-binding protein, or SREBP, pathway which it refers to as MDV4463. Read More Receive MDVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (MDVN) and its competitors with MarketBeat's FREE daily newsletter. Email Address MDVN Stock News HeadlinesCanucks goalie Thatcher Demko will not play in Game 7May 19, 2024 | msn.com7 Tips For Communicating With An Angry Spouse (Without Making It Worse)May 18, 2024 | msn.com5 Stocks Poised to Soar Under Trump's PresidencyWith the next presidential cycle heating up and Trump leading the charge, major market shifts are already taking shape. For investors who position early, the opportunities could be significant. That’s why we’ve just released a brand-new report: 📈 “5 Best Stocks to Buy Under Trump’s Presidency.”July 25 at 2:00 AM | Darwin (Ad)Mike Budenholzer Vows To Compete For Championships After Signing 5-Year Deal Worth Over $50 Million As Suns Head CoachMay 11, 2024 | msn.comTo spite the woke, I will unashamedly vote for Israel at EurovisionMay 11, 2024 | msn.comNotable ETF Outflow Detected - HYLBMarch 27, 2024 | nasdaq.comNearly a thousand take chilly plunge off Oak Street Beach for annual fundraiserJanuary 28, 2024 | msn.comPackers beat Bears 17-9 to clinch playoff spot, head to DallasJanuary 8, 2024 | msn.comSee More Headlines MDVN Stock Analysis - Frequently Asked Questions How were (MDVN)'s earnings last quarter? (MDVN) (NASDAQ:MDVN) posted its earnings results on Tuesday, August, 9th. The biopharmaceutical company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.27 by $0.02. (MDVN)'s revenue for the quarter was up 17.4% compared to the same quarter last year. What other stocks do shareholders of (MDVN) own? Based on aggregate information from My MarketBeat watchlists, some other companies that (MDVN) investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX) and (KITE) (KITE). Company Calendar Last Earnings8/09/2016Today7/25/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryBiotechnology Current SymbolNASDAQ:MDVN CIK1011835 Webwww.medivation.com Phone+1-415-5433470FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:MDVN) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (MDVN) Please log in to your account or sign up in order to add this asset to your watchlist. Share (MDVN) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.